Compare Charles River Laboratories Intl. Inc (CRL) vs MasterCard Inc (MA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs MasterCard Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $229.26 (market cap $11.14B), while MasterCard Inc trades at $538.52 (market cap $475.39B). The key difference: MasterCard Inc is far larger — about 42.7× Charles River Laboratories Intl. Inc's market cap, and MasterCard Inc pays a 0.65% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | MA | |
|---|---|---|
Market Cap | $11.14B | $475.39B |
Sector | Health | Consumer Cyclical |
52-Week High | $233.60 | $598.96 |
52-Week Low | $145.57 | $471.55 |
Enterprise Value | $14.00B | $486.13B |
Volume | — | 4,635,698 |
Dividend Yield | — | 0.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Mastercard (MA) trades at $538.56, up 0.16% on the day, with a bullish technical signal and strong institutional buying interest. The stock exhibits robust fundamentals with revenue growing to $32.79B in 2025 and net income margin at 45.88%, supported by consistent earnings beats. Recent news highlights Mastercard's AI and digital payment initiatives, while analyst consensus remains strongly positive with a $634.27 price target.
Outlook remains favorable given earnings momentum and strategic positioning in digital payments, though high valuation multiples and competitive fintech disruption pose risks. Upside potential is supported by Wall Street's buy ratings and institutional accumulation, but investors should monitor payment industry evolution and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →
